Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-076281
Filing Date
2025-08-11
Accepted
2025-08-11 18:56:36
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 22488
2 EXHIBIT 99.1 tm2523148d1_ex99-1.htm EX-99.1 62235
3 EXHIBIT 99.2 tm2523148d1_ex99-2.htm EX-99.2 63075
  Complete submission text file 0001104659-25-076281.txt   149760
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713 248-681-9815
Opus Genetics, Inc. (Subject) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)